MD (Radiation Oncology) · MBBS · ESMO · ASCO · FRSPH
A dynamic oncologist with expertise spanning radiation oncology, medical oncology, clinical research, and palliative care — committed to evidence-based, patient-centred cancer treatment across Kolkata.
OPD Timings & Locations
About
Dr. Suman Meyur is a consultant oncologist with an MD in Radiation Oncology (First Class) from IPGMER & SSKM Hospital, West Bengal University of Health Sciences, and an MBBS (First Class) from Calcutta National Medical College. He is currently Deputy-in-Charge of Medical Oncology at Saroj Gupta Cancer Centre & Research Institute (SGCCRI), Thakurpukur, and a Specialist Consultant in the Department of Oncology at B.R. Singh Hospital (GOI), Kolkata.
A Visiting Faculty for Biostatistics and Advanced Epidemiology at NSHM Knowledge Campus under MAKAUT, Dr. Meyur blends academic rigour with frontline clinical practice across multiple centres in the city.
Certified by Harvard Medical School (2024), Stanford University (2016 & 2025), and the NIH/NIDA (2024), he carries internationally recognised credentials in oncology, clinical research, and evidence-based medicine.
Specializations
Hypofractionated palliative radiotherapy, concurrent chemoradiation, and management of oral, pharyngeal, laryngeal, and nasopharyngeal malignancies — backed by original peer-reviewed research.
Post-mastectomy hypofractionated radiation, HER2-targeted therapy, and comprehensive care from early-stage to metastatic breast cancer. Led prospective randomised dosimetric trials.
Single-centre prospective study experience in GI stromal tumours; systemic and radiation management of colorectal, pancreatic, and hepatobiliary cancers.
Real-world evidence-based management of metastatic hormone-sensitive prostate cancer including triplet therapy — co-authored in a landmark multicentre Indian study (2024).
Certified under the National Programme for Palliative Care (Govt. of West Bengal). Research focus on quality-adjusted survival and palliative intent radiotherapy for Stage IV disease.
Co-PI in a Phase II Tipiracil/Trifluridine trial; peer reviewer for Elsevier and CG Publishing. Proficient in IBM SPSS, STATA, RevMan, and Elekta ONCENTRA TPS.
Triplet therapy in metastatic hormone-sensitive prostate cancer: A real-world Indian multicentre study.
Epidemiology, prognostication and treatment outcome of gastrointestinal stromal tumour: A single centre prospective study.
A pilot study on feasibility, toxicity and efficacy of novel hypofractionated radiation therapy in advanced non-nasopharyngeal head and neck carcinoma treated with palliative intent.
Dynamics of Decision-Making in Medical Pluralism: A Systematic Review of Conceptual Models.
The incidence of hypothyroidism in patients of head and neck carcinoma treated with radiotherapy and added risk of hypothyroidism with the addition of chemotherapy.
Comparison of conventional and hypofractionated radiation after mastectomy in locally advanced breast cancer: a prospective randomised study on dosimetric evaluation and treatment outcome.
Analysis of Volumetric Dosimetry of Target Volumes and Organs at Risk on ICRU Point Based Dose Planning in CT-Guided HDR Intracavitary Brachytherapy to Carcinoma Cervix.
A Study on Optimization of Dose Distribution by Altering Dose Prescription Points in Post-Mastectomy Hypofractionated Chest Wall Irradiation.
Does Treatment Choice Vary with Disease? An Analysis of Demographic Factors and Disease Burden.
Exploration of Personality Factors and their Effects on People's Decision Making of Complementary and Alternative Medicine.
Primary extra nodal lymphoma: A rare case of gnathic involvement.
Role of primary care providers in dengue prevention and control in the community: practitioners' and local laypersons' perspectives in Dhaka, Bangladesh.
Comparison between Two Regimens of Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. [Poster]
Memberships
Contact
For consultations, second opinions, or general enquiries, reach out via phone, email, or the form. All messages are responded to within 24 hours.
Dr. Meyur's team will get back to you shortly.